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Peritoneal dialysis (PD) patients with sarcopenia have increased risk of 
mortality. There is consensus that sarcopenia should combine assessments of 
muscle function and mass. We wished to determine the effect of using different 
operational definitions in PD patients.  
Methods 
Hand grip strength (HGS) and segmental bioimpedance derived appendicular lean 
mass (ALM) were measured and the prevalence of sarcopenia determined using 
the Foundation for the National Institutes of Health Sarcopenia Project 
(FNIH), European Working Group on Sarcopenia Older Persons (EWGSOP), and 
Asian Working Group on Sarcopenia (AWGS) definitions. 
Results 
We studied 155 PD patients, 95 men (61.3%), mean age 63.0 ±14.9 years, 
37.4% diabetic, treated by PD 9 (3-20) months with a HGS of 22.5 (15.5-30.2) 
kg, weight 73.6 ±16.6 kg, % body fat 31.4 ±4.2, and ALM index 7.52 ±1.40 kg/m2. 
More patients were defined with muscle weakness using the EWGSOP compared 
to the FNIH criteria (X2=6.8, p=0.009), whereas fewer patients met the 
EWGSOP criteria for muscle wasting compared to FNIH body mass index 
adjustment (X2=7.7, p=0.006). However, when combining both criteria, there 
was no difference in the prevalence of sarcopenia between the different 




We report a much lower prevalence of sarcopenia compared to studies in 
haemodialysis patients. Although there may be an element of patient selection 
bias, PD patients are not subject to changes in hydration and electrolytes with 
haemodialysis, which can affect HGS and muscle mass measurements. Using HGS 
and segmental bioimpedance we found similar prevalence of sarcopenia using 




Loss of muscle mass, often referred to as sarcopenia, is associated with 
an increased risk of mortality in the general population [1]. Patients with chronic 
kidney disease are at increased risk of muscle loss due to multiple factors, 
including dietary restrictions, metabolic acidosis, inflammation, urinary protein 
losses and reduced physical activity [2-4]. Additionally, peritoneal dialysis (PD) 
patients lose protein in the spent dialysate [5]. Sarcopenia in PD patients has 
been reported to be an independent risk factor for mortality [6]. 
However, muscle mass declines as part of the normal physiologic process 
of aging, with estimates of losses between 1.0-1.5%, starting after the age of 
thirty [1]. To differentiate age-associated loss of muscle strength that is not 
caused by neurologic or muscular disorders, termed dynapenoa, from 
pathological loss of muscle mass, classifications of sarcopenia now include a 
measure of muscle function in addition to demonstrating muscle loss, as the rate 
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of decline in muscle strength is greater than the rate of loss of muscle mass 
strength, so that muscle strength can diminish, even while muscle mass is 
maintained or even increased [7]. 
Previous reports in PD patients have used a variety of measures to 
estimate muscle mass, with marked differences in the reported prevalence 
depending on how muscle mass was estimated [8], with increased prevalence 
when using creatinine kinetics to estimate muscle mass [9]. However, even when 
using dual energy absorption spectrometry or bioimpedance to measure muscle 
mass [10,11], there have been marked variations in the reported prevalence of 
sarcopenia ranging from 11-31% [12,13]. We therefore decided to review the 
prevalence of sarcopenia in our prevalent cohort of PD patients and comparing 
the prevalence using current guideline recommendations from Europe, North 
America and Asia [14-17]. 
 
Methods 
We retrospectively assessed the prevalence of sarcopenia in adult PD 
patients who had attended the outpatient clinic of a university hospital for 
routine assessment of peritoneal membrane testing [18]. Peritoneal transport 
was calculated as the four hour peritoneal dialysate effluent creatinine to serum 
ratio, weekly urea clearance (Kt/Vurea) and dietary protein nitrogen appearance 
calculated by standard methods from 24-hour urine and peritoneal dialysate 
effluent samples [18]. No patient had been treated for PD peritonitis or had an 
acute hospital admission within the preceding 3 months. Patients with chronic 
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infections, systemic inflammatory diseases and those receiving chemotherapy 
were excluded from study. Relevant medical history and medications were 
obtained from hospital computerised records. Hand grip strength (HGS) was 
measured using the grip-D strength dynamometer (Takei Scientific Instruments 
Co, Nigata, Japan). Patients were instructed and shown how to use the strength 
gauge, and measurements were made according to the manufacturer’s 
recommendations with patients asked to make their maximal voluntary exertion. 
Three measurements were made with the dominant (stronger) arm, and the 
maximal value recorded.  
Multifrequency bioelectrical impedance assessments (MFBIA) were made 
with an 8 electrode multi-frequency segmental bioimpedance device (InBody 
720, Seoul, South Korea) using a standardised protocol, after the patient had 
passed urine and drained out peritoneal dialysate [19,20]. The bioimpedance 
machine was regularly serviced and calibrated. Blood tests were taken 
concurrently and analysed by standard methods for urea, creatinine, albumin, 
haemoglobin, C-reactive protein (CRP) and N-terminal probrain natriuretic 
peptide (NTproBNP) [20,21]. 
Patient co-morbidity was assessed using the Davies-Stoke co-morbidity 
scoring system [22]. Sarcopenia was defined according to the Foundation for 
the National Institutes of Health Sarcopenia Project (FNIH) cut off weakness 
with a HGS of < 26 kg for men and < 16 kg for women [14], and then appendicular 
muscle mass of <19.75 kg for men or < 15.02 kg for women, or a ratio of 
appendicular lean mass to body mass index (BMI) < 0.789 for men and < 0.512 for 
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women [15]; the European Working Group on Sarcopenia in Older People 
(EWGSOP) muscle weakness HGS cut off of < 30 kg for men, < 20 kg for women 
coupled with an appendicular lean mass index (ALMI) of < 7.23 kg/m2 for men 
and < 5.67 kg/m2 for women [16], and the Consensus Report of the Asian 
Working Group on Sarcopenia (AWGS) with a HGS cut off of < 26 kg for men 
and < 18 for women, and an ALMI of < 7.0 kg/m2 for me and < 5.7 kg/m2 for 
women [17]. We calculated prevalence rates of sarcopenia for all patients 
according to the different clinical guideline recommendations.  
Our retrospective audit complied with the UK National Health Service 
(NHS) guidelines for clinical audit and service development with all patient data 
anonymised and complied with UK National Institute for Clinical Excellence 
(NICE) best practices, www.nice.org.uk/media/796/23/bestpracticeclinicalaudit.pdf.  
 
Statistical analysis 
Data is presented as mean ± standard deviation, median (interquartile 
range), or as percentage. Standard statistical tests were used to analyse data, 
(D'Agostino & Pearson normality test, t test, Mann Whitney U test, Chi square 
test) with appropriate corrections made for multiple testing, where appropriate. 
Univariate correlation was by Pearson or Spearman analysis, depending upon 
whether variables were normally distributed. Statistical analysis used Prism 7.0 
(Graph Pad, San Diego, USA) and Statistical Package for Social Science version 
24.0 (IBM Corporation, Armonk, New York, USA). Statistical significance was 




One hundred and fifty-five patients had measurements of HGS, MFBIA 
body composition and peritoneal membrane assessment (table 1). There was a 
positive correlation between HGS in the dominant arm and appendicular lean 
mass in that dominant arm (figure 1), r2=0.39, p<0.001 for all patients. We 
classified patients as having muscle weakness according to the cut-off 
definitions for HGS, reduced muscle mass, and then sarcopenia based on the 
combination of both muscle weakness and muscle loss (figure 2). More patients 
were defined as having muscle weakness using the EWGSOP compared to the 
FNIH criteria (X2=6.8, p=0.009), whereas fewer patients met the EWGSOP cut-
off criteria for muscle wasting compared to the FNIH criteria using the body 
mass index (BMI) adjustment (X2=7.7, p=0.006). However, when combining both 
criteria, there was no difference in the prevalence of sarcopenia between the 
different recommended definitions.  
There was no difference in prevalence of HGS weakness between those 
with and without diabetes (X2=0.01, p=1.0), ethnicity (X2=0.7, p=0.7), or PD 
modality (X2=1.4, p=0.5). Similarly, there was no difference in prevalence of low 
appendicular lean mass between those with and without diabetes (X2=0.1, p=0.9), 
ethnicity (X2=0.7, p=0.7), or PD modality (X2=2.9, p=0.2). 
As significantly more patients had muscle weakness (dynapenia) than loss 
of muscle mass, we compared patients using the EWGSOP criteria. Both male 
and female PD patients who had reduced HGS were older, and had an increased 
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ratio of extracellular water (ECW) to total body water (TBW) (table 2). Male 
patients with dynapenia weighed less, and had less muscle mass, even when 
indexed for height, and also had lower serum albumin, whereas there were no 
differences for women (table 2). There were no differences in residual renal 
function, peritoneal dialysis adequacy or normalised protein nitrogen appearance 
rate between groups. 
We then compared patient groups according to EWGSOP criteria for 
muscle loss (table 3). HGS was lower for those male patients with reduced 
muscle mass, but not for female patients. Apart from less muscle mass, patients 
with reduced muscle weighed less. Female patients with less muscle mass had 
lower BMI and less body fat, whereas male patients with reduced muscle mass 
had a greater percentage of body fat (table 3). 
 
Discussion 
 As patients with sarcopenia have an increased risk for mortality [1], then 
it is essential to have screening tests to detect sarcopenia. Although there is no 
universally agreed consensus on defining sarcopenia, working groups have 
generally combined a functional assessment of muscle strength, typically HGS in 
combination with a loss of appendicular muscle mass [14-17].  
Muscle mass and strength decline as part of the normal aging process. 
Dynapenia is used to describe age-associated loss of muscle strength that is not 
caused by neurologic or muscular disorders and generally the rate of decline in 
muscle strength is greater than the rate of loss in muscle mass [7]. Although 
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older patients are more likely to develop sarcopenia, clinical guidelines do not 
specify age cut-offs [14-17].  Previous studies have noted, particularly for 
haemodialysis patients, that the relationship between muscle strength and mass 
has been weak [8,16]. However, as muscle contains a relatively high amount of 
water, then the water content of muscle changes with hydration status, and so 
measurements of muscle mass differ if measured pre- compared to post-dialysis 
[24,25]. In addition, haemodialysis patients dialysing with an arterio-venous 
fistula have increased water content of the arm, which again alters the 
measurement of arm muscle mass [26,27]. There have been fewer studies in PD 
patients, but again these have often been confounded by the methods used to 
estimate muscle mass [28,29]. Using segmental, rather than total body 
bioimpedance, we were able to measure appendicular muscle mass and also 
compare HGS with muscle mass in the dominant arm and noted a significant 
positive association. 
 As expected, muscle mass and HGS were greater in male patients, and 
younger patients, and female patients had greater body fat mass. Using the 
definitions for sarcopenia [14-17], then all three work group definitions showed 
that muscle weakness was more commonly found than reduced muscle mass, 
which is in keeping with other reports [12,13]. Significantly more patients had 
muscle weakness using the EWGSOP compared to the FNIH cut-off. The normal 
ageing process is associated with not only muscle loss, but also a gain in 
abdominal fat, and this has led to the concept of sarcopenic obesity [30]. As 
such, the FNIH proposed scaling muscle mass for BMI, and using their cut off, 
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then more patients were classified as having reduced muscle mass compared to 
using the EWGSOP criteria. However, when using their definitions of sarcopenia, 
combining reduced HGS and muscle mass, then there was no difference in the 
prevalence of sarcopenia between these different guideline recommendations. 
Peritoneal dialysis patients are exposed to glucose in the dialysate, and 
absorption of glucose may potentially lead to weight gain and an increased BMI 
[31]. This may help to explain the differences in muscle mass adjusted for 
height compared to BMI, without corresponding differences in muscle strength. 
 We found no association between either residual renal function, or the 
amount of urea clearance by peritoneal dialysis, or total urinary and peritoneal 
clearance and sarcopenia, or either of its composites. Similarly, we did not 
observe differences in patient co-morbidity between the groups using a scoring 
system devised for UK PD patients [22]. A previous report suggested an 
association between muscle weakness and congestive heart failure [28], but we 
did not find any differences in the cardiac biomarker NTproBNP between 
groups. Male patients with normal HGS strength were significantly heavier, and 
had both absolute less muscle mass, and also when indexed for height and BMI. 
Although there were the same trends for female patients, these did not reach 
statistically significant difference, similarly there was a trend for weaker 
patients to have more fat. The ratio of extracellular water to total body water 
was greater for patients with reduced HGS, which would be in keeping with a 
reduction in intracellular water and cell mass. 
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 Patients with reduced muscle mass weighed less, and female patients had 
greater muscle loss and also when adjusted for height. In addition, female 
patients had increased absolute body fat, and also body fat was indexed for 
height. Male patients with reduced muscle mass had an increased percentage 
body fat. HGS was reduced in male patients with muscle loss, but not in female 
patients.  Although muscle energy generation may potentially be impaired in 
uraemia, so that muscle strength and mass may differ [30], we noted a 
significant correlation between HGS and appendicular lean mass in the arm. As 
such the difference observed between genders may simply reflect differences 
in patient selection for PD, and a smaller number of female patients. 
Alternatively, as female patients generally have greater body fat, and more fat 
in their arms, then this may account for the differences observed [32].  
 Several studies have observed an association between sarcopenia and 
increased mortality [1,6].  We only report an observational cross-sectional study 
as the number of patients changing modality in UK centres remains high, 
predominantly due to the transfers from peritoneal dialysis to transplantation 
and haemodialysis, which may add confounding to longitudinal studies of 
peritoneal dialysis patients. 
 Overall, we report a prevalence of sarcopenia of 11.0-15.5% using the 
different guideline definitions, which compares to 4-63% reported from a 
variety of studies, including those  from patients with chronic kidney disease not 
on dialysis, to patients initiating and established on haemodialysis [32]. The 
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lower prevalence reported in our cohort of PD patients may reflect selection 
bias in terms of selecting patients for peritoneal dialysis.  
However, by studying PD patients without the confounders of changes in 
hydration status between haemodialysis sessions, and the effect of an arterio-
venous fistula on the size of the arm, and also using segmental bioimpedance to 
measure appendicular lean mass rather than relying on other methods which 
have been recognised to over-estimate muscle loss [29,30], may account for 
lower prevalence observed. In addition, compared to previous studies which have 
reported marked differences between the operational definitions of sarcopenia 
[8], we found that the prevalence did not differ between guideline definitions.  
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Figure 1. Spearman univariate correlation between appendicular lean mass (ALM) 





Figure 2. Percentage of patients with muscle weakness using the Hand grip 
strength (HGS) cut offs for European Working Group on Sarcopenia in Older 
People. Sarcopenia (EWGSOP), the Foundation for the National Institutes of 
Health Sarcopenia Project (FNIH), Consensus Report of the Asian Working 
Group on Sarcopenia (AWGS), and then percentage of patients with reduced 
muscle according to FNIH appendicular lean mass (FNIH-ALM), and body mass 
index (BMI) and then the percentage of patients with sarcopenia meeting the 
combined criteria.  ** p<0.01 vs EWGSOP 
  
Table 1. Peritoneal patient demographics. Values expressed as integer, mean ± 
standard deviation, median (interquartile range). Continuous ambulatory 
peritoneal dialysis (CAPD), automated peritoneal dialysis (APD). 
 
variable  
Male gender (%) 95 (61.3) 
Age years  63.0 ±14.9 
Diabetic (%) 58 (37.4) 
Ethnicity White/Asian/Black (%) 74 (47.7), 48 (31.0), 33 (21.3) 
Systolic  blood pressure mmHg 140.0 ±23.2 
Diastolic blood pressure mmHg 79.2 ±15.2 
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Patients prescribed anti-hypertensives (%) 119 (76.8) 
Peritoneal dialysis treatment months 9.0 (3-20) 
CAPD/APD/APD with day time exchange (%) 43 (27.7), 39 (25.2), 73 (47.1) 
4-hour dialysate/serum creatinine 0.73 ±0.12 
Weekly urinary Kt/Vurea 0.87 (0.4-1.4) 
Weekly peritoneal Kt/Vurea 1.11 (0.4-1.4) 
Total weekly Kt/Vurea 2.13 ±0.71 
Urinary Creatinine clearance ml/min 4.4 (2.2-7.0) 
Weight kg 73.6 ±16.6 
Fat free mass kg 50.4 ±11.8 
Fat mass kg  23.6 ±11.1 
Appendicular mass index kg/m2 7.52 ±1.40 
Hand grip strength kg 22.5 (15.5 – 30.2) 



















Table 2. patients divided into those with muscle weakness (dynapenia) according 
to the European Working Group on Sarcopenia in Older People (EWGSOP) cut 
off for hand grip strength (HGS). Duration of peritoneal dialysis treatment (PD 
months), weekly urinary urea clearance (Kt/Vu) and peritoneal clearance (Kt/Vp), 
and total weekly urea clearance (Kt/Vt), normalised protein nitrogen appearance 
rate (nPNA), body mass index (BMI), skeletal muscle mass (SMM), skeletal 
muscle mass index (SMMI), appendicular lean mass (ALM), appendicular lean 
mass index (ALMI), extracellular water (ECW), total body water (TBW), 
haemoglobin (Hb), serum albumin (Alb), C reactive protein (CRP), N-terminal 





gender Female Female Male Male 
dynapenia No yes No yes 
HGS kg 24.0±2.6*** 12.9±3.6 38.4±6.5*** 20.9±6.2 
Patients 44 17 67 26 
Age years 57±12** 67±13 56±15*** 68±14 















Weekly Kt/Vt 2.47±0.94 2.05±0.69 2.05±0.91 2.09±0.75 
nPNA 
g/kg/day 
0.88±0.24 0.92±0.20 0.87±0.24 0.94±0.20 
Weight kg 68.1±8.4 66.4±13.5 83.5±16.6** 73.8±14.4 
BMI kg/m2 26.4±6.2 26.9±5.6 27.8±5.0* 25.6±4.3 
SMM kg 22.8±4.9 20.9±3.5 33.3±5.2*** 28.4±5.7 
SMMI kg/m2 8.85±1.32 8.40±1.07 11.15±1.27*** 9.79±1.38 
ALM kg 17.0±4.2 16.0±3.2 26.7±4.2*** 22.8±5.2 
ALMI kg/m2 6.56±1.16 6.41±0.94 8.68±0.93** 7.85±1.20 
ALM/BMI 0.65±0.13 6.41±0.94 0.96±0.19** 0.90±0.21 










9.86±4.9 11.1±4.3 7.63±4.0 7.38+3.8 








ECW/TBW 0.393±0.006* 0.401±0.014 0.394±0.013** 0.402±0.012 
Hg g/L 112.7±18.6 107.7±16.4 113.8±13.9 107.7±15.7 
Alb g/L 38.6±4.6 37.3±4.8 38.9±4.5** 36.4±4.4 






































Table 3. patients divided into those with muscle loss according to the European 
Working Group on Sarcopenia in Older People (EWGSOP) cut off for muscle loss. 
Hand grip strength (HGS), duration of peritoneal dialysis treatment (PD 
months), weekly urinary urea clearance (Kt/Vu) and peritoneal clearance 
(Kt/Vp)., and total weekly urea clearance (Kt/Vt), normalised protein nitrogen 
appearance rate (nPNA), body mass index (BMI), skeletal muscle mass (SMM), ), 
skeletal muscle mass index (SMMI), appendicular lean mass (ALM), appendicular 
lean mass index (ALMI) , extracellular water (ECW), total body water (TBW), 
haemoglobin (Hb), serum albumin (Alb), C reactive protein (CRP), N-terminal 
probrain natriuretic hormone (BNP).  * p<0.05, **<0.001 , *** <0.001 vs reduced 
muscle mass group. 
 
gender Female Female Male Male 
Muscle mass Normal Reduced Normal Reduced 
HGS kg 17.4±6.5 16.0±5.4 29.0±10.9* 21.3±7.9 
Patients 23 38 39 55 
Age years 63±14 64±14 62±15 70±18 













Weekly Kt/Vt 2.13±0.61 2.58±1.11 2.07±0.69 2.08±0.76 
nPNA 
g/kg/day 
0.84±0.20 0.99±0.16 0.90±0.26 0.87±0.21 
Weight kg 70.5±14.5*** 49.7±6.4 79.4±15.8*** 67.2±12.3 
BMI kg/m2 27.7±5.7*** 21.4±3.0 26.8±4.6 25.2±5.1 
SMM kg 22.8±3.6*** 16.5±2.2 31.8±5.8*** 22.7±2.5 
SMMI kg/m2 8.91±1.0*** 7.07±0.69 10.6±1.33*** 8.51±1.08 
 19 
ALM kg 17.4±3.0*** 11.5±2.0 25.1±4.7*** 17.6±1.9 
ALMI kg/m2 6.77±0.77*** 4.92±0.69 8.46±1.02*** 6.56±0.71 
ALM/BMI 0.65±0.15* 0.54±0.09 0.95±0.19*** 0.72±0.12 










11.22±4.66* 7.74±2.4 7.23±3.75 9.06±4.39 








ECW/TBW 0.398±0.013 0.398±0.008 0.398±0.014 0.400±0.012 
Hg g/L 109.9±16.3 109.2±23.0 109.1±15.0 116.8±14.9 
Alb g/L 37.7±4.8 37.6±4.3 37.4±4.8 37.8±3.8 
CRP mg/L 3 (1-10)* 7 (1-29) 4 (1-14) 5 (4-9) 
BNP pg/mL 2570(1429-
4465) 
3215(1883-
13167) 
4774(1214-
18004) 
8330(5641-
12728) 
 
